ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2115

Altered Serum Levels of Bone Metabolism Markers in Rheumatoid Arthritis

Lang Jing Zhu1, Xia Ouyang1, Lie Dai1, Dong Hui Zheng1, Ying Qian Mo1, Xiu Ning Wei1, Chan Juan Zou2 and Bai Yu Zhang1, 1Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, 2Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Bone metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction and disability. Previous studies showed abnormal activation of osteoclasts as well as altered skeletal bone metabolism and co-morbid conditions in RA. Tumor necrosis factor receptor-associated factor (TRAF) 6 is one of the critical modulator in differentiation and resorption activity of osteoclasts. New biochemical markers of bone formation showed contradictory results in different studies, although markers of bone resorption have shown significant increase in patients with RA. This study aimed to evaluate serum levels of bone metabolism markers and their correlation with synovial TRAF6 expression, as well as clinical and biological parameters that reflect the activity and severity of RA.

Methods: Serum C-terminal telopeptide of type I collagen (CTX-I), N-terminal propeptide of type I collagen (PINP) and N-terminal midfragment of Osteocalcin (N-MID.OC) was tested by chemiluminescence in 30 patients with active RA, as well as 60 age and gender matched healthy controls. Synovial tissue samples were obtained by needle biopsy from RA patients, and semiquantitative analysis was performed to evaluate the intensity of TRAF6+ cells. Serological and clinical parameters that reflect the activity and severity of RA, as well as radiographic joint destruction (Sharp score) were collected simultaneously.

Results: Serum CTX-I level was significantly higher in RA patients compared with healthy controls (0.56±0.37 vs. 0.34±0.21, p=0.004). No significant difference was found in serum PINP or N-MID.OC level. Spearman’s correlation test showed serum PINP and N-MID.OC level of RA patients correlated negatively with morning stiffness (r=–0.450 and –0.267, p=0.016 and 0.046, respectively) and pain VAS (r=–0.247 and –0.354, p=0.049 and 0.045, respectively), but correlated positively with gripping power (r=0.676 and 0.621, p=0.005 and 0.006, respectively). Significant correlation was found between synovial TRAF6 expression and serum PINP level (r=0.381, p=0.038), as well as serum N-MID.OC level (r=0.345, p=0.042). Subanalysis of lining and sublining TRAF6 expression showed that PINP correlated significantly with sublining TRAF6 expression (r=0.353, p=0.046), N-MID.OC correlated significantly with lining TRAF6 expression (r=0.407, p=0.025).

Conclusion: Increased bone resorption and altered skeletal bone metabolism was found in RA. PINP and N-MID.OC may be a helpful biomarker for disease activity in RA. Synovial TRAF6 expression in RA correlated significantly with serum PINP and N-MID.OC level and maybe involved in the pathogenesis of bone metabolism disbalance in RA.


Disclosure:

L. J. Zhu,
None;

X. Ouyang,
None;

L. Dai,
None;

D. H. Zheng,
None;

Y. Q. Mo,
None;

X. N. Wei,
None;

C. J. Zou,
None;

B. Y. Zhang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-serum-levels-of-bone-metabolism-markers-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology